Effective induction of melanoma-antigen-specific CD8+ T cells via Vγ9γδT cell expansion by CD56high+ Interferon-α-induced dendritic cells

Nieda, Mie, Terunuma, Hiroshi, Eiraku, Yuuta, Deng, Xuewen and Nicol, Andrew J. (2014) Effective induction of melanoma-antigen-specific CD8+ T cells via Vγ9γδT cell expansion by CD56high+ Interferon-α-induced dendritic cells. Experimental Dermatology, 24 1: 35-41. doi:10.1111/exd.12581


Author Nieda, Mie
Terunuma, Hiroshi
Eiraku, Yuuta
Deng, Xuewen
Nicol, Andrew J.
Title Effective induction of melanoma-antigen-specific CD8+ T cells via Vγ9γδT cell expansion by CD56high+ Interferon-α-induced dendritic cells
Formatted title
Effective induction of melanoma-antigen-specific CD8+ T cells via Vγ9γδT cell expansion by CD56high+ Interferon-α-induced dendritic cells
Journal name Experimental Dermatology   Check publisher's open access policy
ISSN 1600-0625
0906-6705
Publication date 2014-01-01
Year available 2014
Sub-type Article (original research)
DOI 10.1111/exd.12581
Volume 24
Issue 1
Start page 35
End page 41
Total pages 7
Place of publication Chichester, West Sussex, United Kingdom
Publisher Wiley-Blackwell Publishing
Collection year 2015
Language eng
Formatted abstract
Dendritic cells (DCs) can be differentiated from CD14+ monocytes in the presence of interferon-α (IFNα) and granulocyte/macrophage-colony stimulating factor (GM-CSF) in vitro and are known as IFN-DCs. Circulating blood CD56+ cells expressing high levels of CD14, HLA-DR and CD86 have been shown to spontaneously differentiate into DC-like cells in vitro after their isolation from blood. We show here that IFN-DCs expressing high levels of CD56 (hereafter, CD56high+ IFN-DCs) can be differentiated in vitro from monocytes obtained as adherent cells from healthy donors and patients with metastatic melanoma. These cells expressed high levels of CD14, HLA-DR and CD86 and possessed many pseudopodia. These CD56high+ IFN-DCs may be an in vitro counterpart of the circulating CD56+ CD14+ CD86+ HLA-DR+ cells in blood. Conventional mature DCs differentiated from monocytes as adherent cells in the presence of GM-CSF, IL-4 and TNF-α (hereafter, mIL-4DCs) did not express CD56 or CD14. In contrast to mIL-4DCs, the CD56high+ IFN-DCs exhibited a stronger capacity to stimulate autologous CD56+ Vγ9γδT cells highly producing IFNγ in the presence of zoledronate and IL-2. The CD56high+ IFN-DCs possessing HLA-A*0201 effectively induced Mart-1-modified melanoma peptide (A27L)-specific CD8+ T cells through preferential expansion of CD56+ Vγ9γδT cells in the presence of A27L, zoledronate and IL-2. Vaccination with CD56high+ IFN-DCs copulsed with tumor antigens and zoledronate may orchestrate the induction of various CD56+ immune cells possessing high effector functions, resulting in strong immunological responses against tumor cells. This study may be relevant to the design of future clinical trials of CD56high+ IFN-DCs-based immunotherapies for patients with melanoma.
Keyword IFN α
Immunotherapy
Melanoma-antigen-specific CD8+ T
Vγ9γδT
Zoledronate
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Published online ahead of print 8 Dec 2014

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2015 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 3 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 06 Jan 2015, 12:52:21 EST by System User on behalf of School of Medicine